Intellia Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.06.24	Intellia Therapeutics Appoints Edward Dulac To Succeed Glenn Goddard As CFO (RTTNews)
15.02.24	Intellia Collaborates With ReCode To Develop Gene Therapy For Cystic Fibrosis (RTTNews)
14.11.23	Intellia Therapeutics Say EC Granted Orphan Drug Designation To NTLA-2002 For Hereditary Angioedema (RTTNews)
18.10.23	Intellia Therapeutics: FDA Allows To Begin Phase 3 Trial Of NTLA-2001 - Quick Facts (RTTNews)
13.10.23	Intellia Therapeutics: EMA Grants PRIME Designation To NTLA-2002 - Quick Facts (RTTNews)
16.09.22	Intellia Reports Positive Interim Data For NTLA-2002 In Treatment Of Hereditary Angioedema (RTTNews)
16.09.22	Intellia: Interim Data Show NTLA-2001 Can Profoundly Reduce Serum TTR Levels (RTTNews)
16.09.22	Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis (PR Newswire)
24.06.22	NTLA : Study Of NTLA-2001 On Transthyretin Amyloidosis Shows Serum TTR Reductions Remained Durable (RTTNews)
24.06.22	Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions ... (PR Newswire)
28.02.22	Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sust... (PR Newswire)
16.09.21	Intellia Says FDA Accepts IND For NTLA-5001 To Treat Acute Myeloid Leukemia - Quick Facts (RTTNews)
26.06.21	Intellia Announces Positive Interim Data On Transthyretin Amyloidosis Study (RTTNews)
26.06.21	Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (AT... (PR Newswire)
26.06.21	Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) (GlobeNewswire)
22.12.20	NantKwest Stock Goes North, QURE's HOPE-B Trial On Hold, EU Greenlights First COVID-19 Vaccine (RTTNews)
09.11.20	Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis (GlobeNewswire)
19.10.20	Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) (GlobeNewswire)
02.06.20	NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps (RTTNews)
10.02.20	Stock To Watch: Intellia Therapeutics Inc. (NTLA) (RTTNews)
15.03.18	Data Wrecks EARS, NTLA's Q4 Results Miss Expectations, SNSS On Watch (RTTNews)
03.11.17	DRNA Soars On NASH Deal, JUNO Transcends Expectations, FMI On Solid Footing (RTTNews)
02.11.17	Busy Year Awaits FLKS, Mark Your Calendar For BPMC Data, CLLS Loses Steam (RTTNews)
01.11.17	MBIO Keeps Galloping, GERN On Fast Track, APVO Awes, INSY Continues Descent (RTTNews)
04.10.17	ECYT On A Roll, MannKind Delighted, DRRX Gains On Patent Deal, PTCT Slumps (RTTNews)
22.09.17	IPXL Mulls Merger, QURE Attracts Attention, No Let Up In ICPT Ocaliva Concerns (RTTNews)
29.08.17	So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches Eye (RTTNews)
22.08.17	Investors: Covered-call reports for Box, Foot Locker, Fabrinet, Intellia Therapeutics and Tenet Healthcare (PR Newswire)
22.08.17	Gainers & Losers Of Aug.21: CHRS, GTHX, OTIC, APEN, PETS... (RTTNews)
20.06.17	Gainers & Losers Of June 19: ARNA, NVDQ, CLVS, RWLK, CLSN... (RTTNews)
31.05.17	Gainers & Losers Of May 30: PTGX, ECYT, NTLA, EDIT, CNCE... (RTTNews)
16.02.17	ARDX Kidney Drug Passes Phase 3 Study, EDIT Up On CRISPR News, FDA Nod For VRX (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Intellia Therapeutics Inc

Aktien Top/Flop

Intellia Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten